Thanks Neuro. If the upper end 800 mg BID dose is not currently allowed by the dosing restriction (perhaps Dr. Stoll may clarify this in the conf call), wouldn't it seem logical for BPs to want to see that restiction lifted prior to consummating a deal? BPs have to figure that the FDA could still shoot down CX-717 based on a problem in the 3 month primate tox study.
Also, with Shire becoming the one-stop shop for ADHD, doesn't a deal with them seem increasingly possible? They probably aren't interested in AD/neurodegenerative, and could out-license those themselves to a BP. Or do you think Cortex will prefer a bonafide BP partner like Lilly, Glaxo, etc? Thanks.
Market Data 
Markets 
AI
